{"id":3036,"date":"2026-09-10T08:34:00","date_gmt":"2026-09-10T12:34:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3036"},"modified":"2026-09-10T19:57:28","modified_gmt":"2026-09-10T23:57:28","slug":"rentosertib-doses-first-patient-in-china-phase-iii-ipf-trial","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3036","title":{"rendered":"Rentosertib Doses First Patient in China Phase III IPF Trial"},"content":{"rendered":"

Evidence<\/strong> Regulatory + company disclosure · Discovery<\/strong> September 10, 2026 · Importance<\/strong> 4\/5 · Direction<\/strong> Positive<\/p>\n

\"Rentosertib<\/p>\n

Summary<\/h4>\n

Insilico Medicine reported first-patient enrollment and dosing in GENESIS-IPF-3, a 320-participant, 47-center China Phase III study of the oral TNIK inhibitor rentosertib in idiopathic pulmonary fibrosis. The 52-week randomized, double-blind, placebo-controlled trial uses annualized forced-vital-capacity decline as the primary endpoint and time to first disease-progression event as a key secondary endpoint. The operational milestone moves an AI-originated target and molecule into pivotal testing, but it contributes no new efficacy or safety data.<\/p>\n

What Happened<\/h4>\n

The first participant was dosed at Peking Union Medical College Hospital, and Shanghai Pulmonary Hospital enrolled its first participant the same day. GENESIS-IPF-3 is registered as NCT07687459 and CTR20262475 and is intended to test once-daily rentosertib against placebo for 52 weeks at 47 centers in China. Rentosertib, also known as ISM001-055 and INS018_055, was identified and designed with the company’s Pharma.AI platform and inhibits TRAF2- and NCK-interacting kinase. A prior 12-week Phase IIa study supported advancement with a reported favorable safety profile and dose-related efficacy trends, but it was small and short.<\/p>\n

Deep Analysis<\/h4>\n

Execution validates AI-enabled translation:<\/strong> Moving an AI-derived target and AI-designed small molecule into a randomized Phase III trial is a meaningful platform milestone and tests whether compressed discovery timelines can survive conventional clinical validation. The counterpoint is that trial start measures execution, not predictive superiority; success will still depend on target biology, molecule quality, endpoint sensitivity and study conduct.<\/p>\n

A pivotal design that may be difficult to generalize:<\/strong> A 320-patient China-only study across 47 centers can produce a controlled efficacy estimate efficiently. However, regional standard-of-care use, concomitant antifibrotics, site heterogeneity and a relatively modest sample may complicate global regulatory extrapolation or subgroup interpretation.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: first patient dosed; 320 planned participants; 47 China centers; 52-week randomized placebo-controlled design; annual FVC-decline primary endpoint; disease-progression-event key secondary endpoint. Missing facts: dose, stratification, statistical assumptions, expected readout and regulator alignment outside China. Upgrade evidence would be rapid enrollment with registry reconciliation and prospectively positive FVC and progression results.<\/p>\n

Company and Product Background<\/h4>\n

Insilico Medicine is a Hong Kong-listed biotechnology company that combines generative AI, automation and internal drug development. Rentosertib is its lead wholly developed clinical candidate and is positioned as a potentially first-in-class oral TNIK inhibitor. The company previously received U.S. orphan-drug designation and China breakthrough-therapy designation for the IPF program.<\/p>\n

Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease in which extracellular-matrix deposition reduces lung compliance and gas exchange. Approved antifibrotics slow functional decline but do not reverse established disease. TNIK participates in profibrotic signaling networks; rentosertib is intended to suppress the cellular programs that drive fibrotic progression.<\/p>\n

InSilens Take<\/h4>\n

First dosing is a real development milestone and a high-visibility test of AI-enabled drug discovery, but it should not be confused with clinical validation of the platform or TNIK. The trial’s scientific value will come from a conventional standard: whether rentosertib reproducibly slows FVC loss and disease progression with acceptable chronic safety.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n4 \/ 5 — first Phase III dosing advances a closely watched AI-originated drug into pivotal clinical validation<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nPositive — a verified operational advance, not a judgment on eventual efficacy<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — milestone and study design documented in a same-day Hong Kong exchange filing and company disclosure<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate-low — platform read-through and global regulatory implications remain uncertain until pivotal data are available<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Insilico Medicine reported first-patient enrollment and dosing in GENESIS-IPF-3, a 320-participant, 47-center China Phase III study of the oral TNIK inhibitor rentosertib in idiopathic pulmonary fibrosis. The 52-week randomized, double-blind, placebo-controlled trial uses annualized…<\/p>\n","protected":false},"author":1,"featured_media":3048,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[520,594,595,683],"class_list":["post-3036","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-idiopathic-pulmonary-fibrosis","tag-insilico-medicine","tag-rentosertib","tag-tnik"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3036"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3036\/revisions"}],"predecessor-version":[{"id":3056,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3036\/revisions\/3056"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3048"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}